DEV SITE
Thomas Ragole, MD
Neurology
Locations
Practice Locations
UCHealth Neurosciences Center - Anschutz Medical Campus
720-848-2080
UCHealth Stroke and Brain Aneurysm Center - Anschutz Medical Campus
720-848-2080
Provider Expertise
Clinical Interest for Patients
My main clinical interests are in the care of hospitalized patients with neurologic conditions and treatment and evaluation of immune mediated neuromuscular disorders such as myasthenia gravis, CIDP, inflammatory muscle disease and others.
Care Philosophy
A neurologic diagnosis can be one of the most life changing events in a person's life. I am committed to working alongside my patients to ensure that they are receiving the most up-to-date care and are able meet their goals regardless of diagnosis.
Specialties
- Neurology ( 2018 )
- Neuromuscular Medicine ( 2020 )
Conditions & Treatments
-
Brain and Nervous System
Neuromuscular Diseases
Education & Training
Medical Schools
MD, University of Colorado Denver School of Medicine (2014)
Undergraduate Schools
BA, University of Colorado - Boulder (CO) (2009)
Residency Program
University of California (San Francisco) Program (2018)
Fellowships
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School Program (2019)
Research & Grants
Research Interests for Patients
Improving treatments and outcomes for myasthenia gravis, immune mediated neuropathies and immune mediated myopathies. Evidence-based practice and guideline development for the treatment of hospitalized patients.
information for referring providers
Referral Contact Phone
720-848-2080
Referral Contact Fax
720-848-2106
Clinical Interests for Referring Providers
My main clinical interests include hospital neurology, acute and ongoing treatment and research on autoimmune neuromuscular disease: myasthenia gravis, inflammatory myopathies and inflammatory neuropathies.
Research Interest for Referring Providers
I am interested in the areas where inpatient neurology and neuromuscular disorders overlap with particular focus on: 1 ) improving treatments and outcomes for myasthenia gravis, immune mediated neuropathies and immune mediated myopathies, 2) Evidence-based practice and guideline development for the treatment of hospitalized patients and 3) Improving clinical decision making at all levels of education.